Targeting Activin x GDF signalling pathway.
Unlocking the full power of Activin x GDF biology to treat Pulmonary Hypertension, Obesity and Heart Failure.
Developing transformative therapies.
Our company
At 35Pharma, we are dedicated to designing and developing best-in-class ligand traps that target Activin x GDF biology and address diseases with high unmet medical need including pulmonary hypertension, heart failure and obesity.
We leverage our decades of experience designing and developing ligand traps. This unique therapeutic modality enables tailored multi-specificity and potency which makes ligand traps ideally suited to target the Activin x GDF signaling pathway.
Our experienced team has a proven track record of advancing complex biologics from discovery through clinical validation.
HS235
HS235, our lead candidate, is in clinical development for cardiometabolic disease and pulmonary hypertension.
HS235 was designed to improve pulmonary and cardiac function while simultaneously ameliorating metabolic health. This unique approach addresses the high unmet medical needs in pulmonary hypertension, heart failure and obesity.
News
Subscribe
To receive our press releases, please subscribe to our mailing list
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.